Tests to Detect Cancer Early
Early detection will give you lots of time to change your diet and lifestyle before the condition has time to develop into full blown cancer.
1. cancerireland.ie does NOT benefit financially or otherwise from the inclusion of any product or service listed on this site.
2. The list of laboratories is not complete.
Test is available from:
Litfield House Medical Centre
1 Litfield Place, Clifton
Bristol, BS8 3LS
Phone: +44 (0)117 317 1460
USA and Canada
R.G.C.C. USA LLC
BRANCH OFFICE IN THE U.S.A., NORTH AMERICA CONTINENT & CANADA
3105 Main Street, Rowlett TX 75088, USA
T.: +1 214 299 9449
F.: +1 214 299 9923, +1 972 463 8243
This test will report the number of Circulating Tumor Cells and any positive Circulating Cancer Stem Cells, and the immunophenotype of these cells.
Circulating Tumour Cells
CTCs are cancer cells which have broken away from the primary tumor and have entered the blood stream where they circulate and have the potential to generate metastatic disease. These cells can be isolated and identified and there is growing interest in their detection for the following purposes.
1. The early detection and diagnosis of new cancers
2 Monitoring existing cancers
3 Prognosis – providing information about the risk of recurrence of a current or old cancer
R.G.C.C. Group offers general assays for CTCs and for specific cancers, including breast, colorectal, prostate, malignant melanoma and sarcomas.
Source: R.G.C.C Group
Test available from:
Menarini Silicon Biosystems
The test identifies and counts the number of circulating tumor cells, down to 1 cell, and from an ordinary 7.5 ml blood sample. The cut off limit is 5, so if the patient has less than 5 CTCs the prognosis is far better than if the number is above.
By a cell count over 5, the goal of proper treatment is to lower the count to below 5, which substantially improves the prognosis. Is the number under 5, the doctors will probably choose a milder and less toxic treatment, and can thus save the patient from severe side effects.
With the CTC test it is possible, after as early as 3 weeks, to see if a given treatment works. If not, it can be stopped immediately and replaced by another type of treatment. This saves valuable time by avoiding unnecessary treatment often associated with many side effects, and the CTC test is capable, much better than previously, of predicting a specific prognosis.
Article source: Humlegaarden
Nagalase Blood Test
Test available from:
European Laboratory of Nutrients
3981 LA Bunnik
Phone: +31 30 2871492
Fax: +31 30 2802688
Nagalase in blood is a sensitive test for monitoring the effect of the therapy in patiënts with cancer and certain viral infections, including HIV. Because of the short half-life of nagalase the method is suitable for monitoring various types of therapy. The great sensitivity of the test will help the physician / oncologist to obtain a better understanding of the therapy and to fine-tune the treatment.
Source: European Laboratory of Nutrients
Test available from :
1201 Cumberland Avenue, Suite B
West Lafayette, IN 47906
What is the blood test based on?
The ONCOblot® blood test identifies a specific type of protein in the blood, ENOX2, which exists only on the surface of a malignant cancer cell. The ENOX2 proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for confirmation of cancer presence. The test is a valuable complement to early intervention.
How sensitive is the cancer blood test?
The ONCOblot® Test has been shown to detect cancer as early as Stage 0. The limit of detection is an estimated 2 million cells (2 mm or less tumor mass, roughly the size of a pinhead) compared to several billion cells for a positive mammogram.
Article source: Oncoblot Labs
The CA Profile Plus©
Test available from:
American Metabolic Laboratories
1818 Sheridan Street, Suite 102
Hollywood, FL 33020, USA
HCG Urine Immunoassay
Test available from:
Navarro Medical Clinic
Developed in the late 1950s, by the renowned oncologist, the late Dr. Manuel D. Navarro, the test detects the presence of cancer cells even before signs or symptoms develop. Dr. Navarro found HCG to be present in all types of cancers. The test is based on a theory proposed by Howard Beard and other researchers who contend that cancer is related to a misplaced trophoblastic cell that become malignant in a manner similar to pregnancy in that they both secrete HCG. As a consequence, a measure of the amount of HCG found in the blood or urine is also a measure of the degree of malignancy. The higher the number, the greater is the severity of cancer.
Urine, as opposed to blood or serum, is the preferred specimen for the test.
The test detects the presence of brain cancer as early as early as 29 months before symptoms appear; 27 months for fibro sarcoma of the abdomen; 24 months for skin cancer; 12 months for cancer of the bones (metastasis from the breast extirpated 2 years earlier).
Currently, many cancer patients take advantage of the diagnostic accuracy of the HCG test as an indicator of the effectiveness of their specific mode of therapy. Thousands of cancer survivors have used this test over the years to keep track of their treatment(s) success and check on the status of their remission.
Article source: Navarro Medical Clinic
The AMAS Test
Test available from: Oncolabinc
Physicians around the country are recommending and administering the AMAS test on a regular basis for patients at high risk for cancer, and for follow-up purposes on patients already diagnosed and/or treated for cancer.
Unlike tests such as CEA, which measure less well-defined antigens whose serum levels tend to be inconstant but elevated late in the disease, the AMAS test measures a well-defined antibody whose serum levels rise early in the course of the disease.
A common clinical situation involves signs or symptoms suggesting a disorder which may or may not be malignant. While neither AMAS nor any other clinical laboratory test can by itself answer this question, AMAS test results may help the physician in the diagnostic process.
Note for patients outside the U.S
In an email, Oncolabinc said:
“We will do the AMAS test for European clients, but as stated below, it can be quite difficult. We have a partner in Germany who can run tests for those in Germany and Austria – patients can email us at email@example.com requesting that information if they would like.”
Article source: Oncolabinc
Test available from:
Oncimmune (List of laboratories offering this test worldwide)
EarlyCDT®–Lung is a simple blood test which is ordered by your Doctor to aid in the risk assessment and early detection of lung cancer.
Early in the development of a solid tumour cancer, the body mounts an immune response to certain by-products, or proteins, (tumour antigens) from cancer cells by producing autoantibodies. These autoantobodies which can rise in the earliest stages of cancer, and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual’s blood using a simple blood test, EarlyCDT–Lung.
There is no one type of tumour associated antigen or autoantibody that can be used to detect all or any type of cancer, therefore EarlyCDT–Lung has been developed to measure a panel of 7 autoantobodies associated specifically with lung cancer.
EarlyCDT–Lung has been developed so that individuals at moderate or high risk of developing lung cancer can benefit from an increasing chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
The EarlyCDT–Lung test can also be used in conjunction with diagnostic imaging such as x-ray or CT scan, to further assess the risk of lung cancer being present where indeterminate lung nodules have been detected but which may or may not be a sign of cancer.
This is not a genetic test for predisposition—a positive test may indicate the presence of the disease and an increased risk of malignancy. The test is sent to and performed in the CLIA-certified laboratory in Kansas City, USA. Currently, EarlyCDT–Lung is in use by more than 2000 physicians across the United States, and has aided in the detection of numerous early stage lung cancers. It is now also available in the UK.
Article source: Oncimmune
Hereditary Cancer Genetic Tests
Tests available from:
This test is not for everyone; only high-risk patients should be tested
Most cancer is known as sporadic cancer. This cancer occurs in people who don’t have a family history or changes in their DNA that would increase their risk for cancer. On the other hand, hereditary DNA changes are present since birth and some of these changes can increase the risk of developing cancer. Our tests look for such cancer-causing changes (pathogenic variants) in certain genes.
Pathway Genomics genetic tests screen a number of known genes related to hereditary cancers. The goal of every test is to determine a patient’s risk of cancer. This knowledge can help your physician to develop the appropriate or preventative treatment plan for early detection. If the results of your test indicate an increased risk for cancer, your doctor may order tests like mammograms, colonoscopy and CT scans for any possible diagnosis and immediate intervention.
Source: Pathway Genomics
Screening for Bowel Cancer
In Ireland – a BowelScreen Test Kit is offered free to men and women aged 60-69 by The National Bowel Screening Programme
This is a test you carry out in your own home.
You can also purchase the kit from PrivaPath Diagnostics
Test kits may be supplied by your Health Service or can be purchased in pharmacies and online.